Form 4: Director Johnson Acquires TMO Phantom Stock

Thermo Fisher Scientific Director Jennifer M. Johnson acquired 67.31 phantom stock units through a deferred compensation plan.

Summary

• Jennifer M. Johnson, a Director of Thermo Fisher Scientific Inc. (TMO), acquired phantom stock units.
• The transaction occurred on September 27, 2025.
• She acquired 67.31 phantom stock units at a price of $464.24 per unit.
• These units were credited to her account under the Issuer's Deferred Compensation Plan for Directors.
• Following this transaction, her beneficial ownership of phantom stock units is 541.36.
• Phantom Stock Units are convertible into Common Stock on a 1-for-1 basis.
• Shares are distributable as stock upon cessation of director service (for any reason) or a change of control.

Sentiment

Score: 6

Explanation: Routine director compensation, but the acquisition of additional phantom stock units by a director is generally viewed as a positive signal of alignment with shareholder interests, even if it's part of a deferred compensation plan.

Positives

• Director Jennifer M. Johnson increased her beneficial ownership of phantom stock units by 67.31 units, demonstrating continued alignment with shareholder interests.
• The acquisition was part of a deferred compensation plan, indicating a structured approach to director remuneration and long-term commitment.

Negatives

• NA

Risks

• NA

Future Outlook

NA

Management Comments

• Jennifer M. Johnson disclaims beneficial ownership of securities held by Franklin Templeton subsidiaries, where she serves as President, CEO, and Director.

Industry Context

This transaction reflects standard director compensation practices, where equity-based awards, often deferred, are used to align director interests with long-term shareholder value. Such plans are common across various industries for publicly traded companies.

Comparison to Industry Standards

• Deferred compensation plans for directors, involving equity-linked units, are a common practice in large-cap companies like Thermo Fisher Scientific, aligning director incentives with long-term company performance.
• The 1-for-1 conversion of phantom stock units to common stock upon cessation of service is a standard feature in such plans, similar to those offered by peers in the life sciences and diagnostics sector.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• Jennifer M. Johnson, also President, CEO, and Director of Franklin Resources, Inc. (Franklin Templeton), disclaims beneficial ownership of securities of Thermo Fisher Scientific Inc. held by Franklin Templeton subsidiaries.

Stakeholder Impact

• Shareholders: Increased alignment of director's interests with long-term shareholder value through equity-based compensation.
• Directors: Compensation structure includes deferred equity, linking their remuneration to company performance.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 reports a routine acquisition of phantom stock units by a director as part of a deferred compensation plan. While it indicates continued director alignment, it does not provide new material information about the company's operational or financial performance that would warrant a change in investment recommendation. It's a standard compensation event.

Keywords

Thermo Fisher Scientific, TMO, Jennifer M. Johnson, Form 4, insider transaction, phantom stock, deferred compensation, director compensation